In conclusion the leukotrienes appear to fulfill the major criteria as mediators of inflammation. They have been shown to be present at a variety of inflammatory sites and to be generated by cells involved in inflammatory sequelae following an inflammatory stimulus. Their effects on the microvasculature and inflammatory cells are consistent with a pro-inflammatory role and the effects of LTB4 in particular on a range of immune responses may indicate a role in the more chronic phases of inflammatory disease. It remains to be conclusively proven that specific inhibition of LT generation or antagonism of LT action will lead to a reduction in inflammatory symptomology in human disease however the data so far provides some hope that drugs with such properties may find a place in the medicinal armamentarium in the relatively near future.